Results of the treatment of adrenocortical cancer patients at the Maria Sklodowska-Curie National Research Institute of Oncology – Krakow Branch
, 1, 1, 1, 1, 1
Streszczenie
Introduction.Adrenocortical carcinoma (ACC) has an incidence of 1–2 cases per million and the 5-year overall survival (OS) is 16–47%. Surgery is the treatment of choice. Post-operative radiotherapy has been shown to prolong overall survival and the purpose of this work was to show our own, first time in Poland, results of adjuvant radiotherapy in treating this disease.
Material and methods.Between 2012 and 2021, 12 patients with ACC were treated. The analyzed group included 9 women and 3 men at a mean age of 44 years (range: 33 to 76 years). A significant increase of tumor size was found in 30% of the subjects. In the analyzed group, 12 patients were qualified to adjuvant radiotherapy, but it was feasible only in 7 patients. The other 5 patients did not undergo radiotherapy. Two patients were disqualified due to metastatic disease and in 3 patients radiotherapy could not be performed due to excessive tumor size and too high a risk of complications within the critical organs.
Results.3 out of 7 patients who received adjuvant radiotherapy are still alive and 4 of them died. Mean overall survival time was 32 months. The 12-month overall survival rate was 80%. In the group of 5 patients who have not received radiotherapy, 2 patients are still alive. The mean overall survival time is 13.5 months and the 12-month overall survival rate is 60%.
Conclusions.Due to rapid disease progression and poor prognosis associated with ACC, patients with tumors located in the adrenal gland require urgent surgical treatment at a reference center. Adjuvant radiotherapy improves treatment results significantly, but is not feasible in some patients due to cancer progression or the tumor location. In patients with ACC, it is important to diagnose the disease and to start adequate treatment as early as possible.
Słowa kluczowe: adrenocortical cancersurgeryradiotherapymitotane
Referencje
- Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013; 49(11): 2579–2586.
- Rachtan J, Sokołowski A, Geleta M, et al. Cancer in małopolska voivodship in 2019. https://nio-krakow.pl/wp-content/uploads/2022/03/nzwwm2019.pdf (10.12.2022).
- Fassnacht M, Dekkers O, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018; 179(4): G1–G46.
- Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014; 35(2): 282–326.
- Bednarczuk T, Bolanowski M, Sworczak K, et al. Przypadkowo wykryty guz nadnercza (incydentaloma) u dorosłych — zasady postępowania rekomendowane przez Polskie Towarzystwo Endokrynologiczne. Endokrynologia Polska. 2016; 67(2): 234–258.
- Otto M, Kasperlik-Załuska A, Januszewicz A, et al. Laparoscopic adrenalectomy for management of incidentaloma and adrenal masses in patients with hormonal hypertension. Arterial Hypertension. 2004; 8(2): 139–146.
- Ciupińska-Kajor M, Ziaja J, Kajor M, et al. Morphological and clinical characterisation of patients with adrenocortical carcinoma. Chirurgia Polska. 2006; 8(2): 146–155.
- Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia Kliniczna, tom 2. Via Medica, Gdańsk 2015: 1102–1111.
- Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014; 35(2): 282–326.
- Tran TB, Postlewait LM, Maithel SK, et al. Actual 10-year survivors following resection of adrenocortical carcinoma. J Surg Oncol. 2016; 114(8): 971–976.
- Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006; 91(7): 2650–2655.
- Maciejewski B, Składowski K. The dose no longer plays a paramount role in radiotherapy (oncology), but time apparently does. Nowotwory. Journal of Oncology. 2022; 72(2): 80–85.
- Maciejewski B. Tumor and normal tissue radiation side effects. Nowotwory. Journal of Oncology. 2022; 72(4): 242–246.
- Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009; 115(13): 2816–2823.
- Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015; 92(2): 252–259.
- Viani GA, Viana BS. Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis. J Cancer Res Ther. 2019; 15(Supplement): S20–S26.
- Gharzai LA, Green MD, Griffith KA, et al. Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2019; 104(9): 3743–3750.
- Zhu J, Zheng Z, Shen J, et al. Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat Oncol. 2020; 15(1): 118.
- Cerquetti L, Bucci B, Marchese R, et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer. 2008; 15(2): 623–634.
- Baranowska-Bik A, Zgliczyńki W. Zespół psychoendokrynny w wybranych endokrynopatiach. Postępy Nauk Medycznych. 2014; XXVII(12): 872–875.
